Caris Q3 2026 Earnings: Revenue Rises 27% as Cash Flow Turns Negative

Caris Life Sciences (Nasdaq: CAI) reported Q3 2026 revenue of $275.4 million, up 27% from $216.8 million a year earlier, while diluted EPS declined to $0.05 from $0.08. Molecular profiling services and higher clinical case volume drove revenue growth, but lower gross margin, rapidly rising operating expenses, and launch-related investment weighed on profit and quarterly cash flow.

Core Earnings Data

For the quarter ended September 30, 2026, molecular profiling remained the primary growth engine. However, operating expenses increased 42%, substantially faster than revenue, as Caris spent more on headcount, research and development, and marketing.

As a result, operating income, net income, and adjusted EBITDA all declined despite the higher revenue base. Quarterly operating and free cash flow also shifted from positive to negative.

Adjusted EBITDA and free cash flow are non-GAAP measures. Caris defines free cash flow as operating cash flow less capitalized software and purchases of property and equipment.

Business and Segment Performance

Molecular profiling services generated $262.7 million, representing about 95% of total revenue. Growth reflected approximately 61,500 clinical cases, up 21%, as well as improvements in average selling price.

Pharma research and development services also grew, but the segment remained a comparatively small contributor to consolidated revenue.

Caris completed more than 358,000 oncology tests during the quarter. It also launched Caris Assure Therapy Response Monitoring and an enhanced version of Caris Assure for therapy selection, expanding the blood-based platform beyond initial treatment selection.

Revenue Growth Did Not Offset Margin and Cash Flow Pressure

Cost of services increased by approximately 34%, faster than the 27% increase in revenue, reducing gross margin from 68% to 66%. Operating expenses rose to $163.0 million from $114.9 million, driven by headcount-related costs, higher R&D investment, and marketing spending. This compressed the operating margin to approximately 7% from about 15% a year earlier.

The cash-flow divergence was more pronounced. Caris used $22.2 million of operating cash during Q3, compared with generating $62.4 million in the prior-year quarter. Management attributed the decline to commercial expansion, marketing, inventory buildup for new product launches, and R&D activity. Capitalized software and property and equipment spending then contributed to a $39.7 million free-cash-flow deficit.

The nine-month figures provide additional context without changing the weak quarterly trend. Operating cash flow for the first nine months of 2026 remained positive at $39.1 million, but nine-month free cash flow was negative $10.8 million, compared with positive $27.2 million in the corresponding 2025 period.

As of September 30, 2026, balance-sheet cash, cash equivalents, and restricted cash totaled $665.3 million, compared with $797.8 million at December 31, 2025. Short-term marketable securities increased to $102.1 million from $2.3 million, while supplies rose to $138.4 million from $63.6 million, consistent with the disclosed inventory investment. Long-term indebtedness was $393.2 million.

2026 Guidance

Caris raised its full-year revenue outlook and reaffirmed its clinical therapy selection volume target. The release did not provide the previous revenue range, so the size of the guidance increase cannot be quantified.

Management Perspective

Founder, Chairman, and CEO David Dean Halbert emphasized the record clinical case volume and the breadth of Caris’ molecular profiling platform. Management is extending Caris Assure into treatment-response monitoring and is targeting the launch of Caris Confirm, a whole-genome tumor-informed minimal residual disease assay, before the end of 2026.

These launches are strategically important because current spending includes inventory, commercialization, and R&D investment tied to new solutions. Their adoption will therefore affect whether recent revenue growth can translate into improved margins and cash conversion.

Recent Insider Transactions

Yahoo Finance’s six-month aggregate data reported 1,789,786 shares purchased across 13 transactions and 1,004,712 shares sold across three transactions, resulting in net purchases of 785,074 shares. Total insider holdings were listed at approximately 137.88 million shares, with net purchases equal to 0.60%.

The latest reported records included sales, derivative exercises or conversions, and director stock grants. All were classified as direct transactions, and the source did not disclose the motivation behind them.

Risks Investors Need to Watch

• Dependence on molecular profiling: This business produced about 95% of quarterly revenue, making clinical case volume, average selling prices, payer coverage, and reimbursement important to overall growth.
• Margin and expense pressure: Gross margin declined by two percentage points while operating expenses rose 42%. Continued spending growth above revenue growth would keep pressure on operating income.
• Cash conversion and inventory: Quarterly operating cash flow turned negative, and the supplies balance increased substantially from year-end 2025 as Caris prepared for new launches.
• New product execution: The returns on commercialization and R&D spending depend partly on the timing, market acceptance, and reimbursement of products including Caris Assure, Caris Confirm, and Caris Detect.

Summary

Caris delivered 27% Q3 revenue growth through higher molecular profiling volume and improved pricing, but faster growth in service costs and operating expenses reduced earnings and pushed quarterly cash flow into negative territory. The raised revenue outlook indicates continued top-line momentum, while the main follow-up issue is whether new product adoption and clinical volume growth can stabilize margins and improve cash conversion.